


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) ~~Use of compounds of the following formula (I) A method for the treatment of treatment of postlesional diseases of ischemic, traumatic or toxic origin, comprising administering an effective amount of a compound of formula (I):~~



wherein X represents OH, (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂;

R₁ is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C₁₋₅) alkoxy groups, (C₁₋₅) alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile;

R₂ is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu and Pro;

Y₁ and Y₂ independently from each other represent H or (C₁₋₅) alkyl;

R₃ and R₄ independently from each other represent H, OH, (C₁₋₅) alkyl or (C₁₋₅) alkoxy, provided that R₃ and R₄ are not both OH or (C₁₋₅) alkoxy; and

R₅ represents H, OH, (C₁₋₅) alkyl or (C₁₋₅) alkoxy;
or a pharmaceutically acceptable salt thereof;
~~for the preparation of a medicament useful in the treatment of postlesional diseases of ischemic,
traumatic or toxic origin.~~

2. (currently amended) The use method according to claim 1, wherein X represents (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂.

3. (currently amended) The use method according to claim 1 or 2, wherein R₃ and R₄ independently from each other represent H, (C₁₋₅) alkyl or (C₁₋₅) alkoxy, provided that R₃ and R₄ are not both OH or (C₁₋₅) alkoxy.

4. (currently amended) The use method according to any of the previous claims claim 1, wherein R₅ represents H, (C₁₋₅) alkyl or (C₁₋₅) alkoxy.

5. (currently amended) The use method according to any of the previous claims claim 1, wherein R₁ is a residue which is derived from one of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted with a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom, or which is derived from Ile.

6. (currently amended) The use method according to claim 5, wherein R₁ is a residue which is derived from Phe, which may optionally be substituted with a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom.

7. (currently amended) The use method according to any of the previous claims claim 1, wherein R₂ is a residue which is derived from the amino acid Gly or Ile.

8. (currently amended) The use method according to any of the previous claims claim 1, wherein in the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-

isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.